Thrivent Financial for Lutherans’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-195,402
Closed -$23.6M 2565
2023
Q1
$23.6M Buy
195,402
+3,162
+2% +$364K 0.06% 382
2022
Q4
$22.1M Buy
192,240
+24,100
+14% +$2.66M 0.06% 391
2022
Q3
$17.2M Buy
168,140
+26,545
+19% +$2.81M 0.05% 433
2022
Q2
$14.4M Buy
141,595
+7,385
+6% +$805K 0.04% 489
2022
Q1
$15.6M Buy
134,210
+8,500
+7% +$983K 0.03% 546
2021
Q4
$14.4M Buy
+125,710
New +$14.3M 0.03% 565
2020
Q4
Sell
-88,000
Closed -$9.85M 2504
2020
Q3
$9.85M Hold
88,000
0.03% 603
2020
Q2
$9.21M Buy
+88,000
New +$9.43M 0.03% 567

Other funds holding BSX.PRA

Thrivent Financial for Lutherans's BSX.PRA Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 195,402 shares — an estimated $23.6M sold.

Thrivent Financial for Lutherans first reported a position in BSX.PRA in Q2 2020 and held it in 8 quarters. The position peaked at $23.6M in Q1 2023. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

  • Thrivent Financial for Lutherans reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 195,402 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $23.6M.
  • Thrivent Financial for Lutherans first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 8 quarters.
  • Thrivent Financial for Lutherans's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $23.6M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.